🧫
NP137 treatment of A549 human cancer cell xenografts
active
experiment
Created: 2026-04-10T14:41:33
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-08833ef2-f2ab-4007-9aa7-5987cee656df
🧫 Experiment Protocol
ValidationCancerNTN1A549 human cancer cell xenografts in miceproposed
This experiment tested the therapeutic efficacy of NP137 in a human cancer xenograft model using A549 cells. The A549 human cancer cell line, which undergoes EMT following TGFβ1 administration, was transplanted into mice. The transplanted mice were then treated with NP137 to assess whether netrin-1 inhibition could decrease EMT in human cancer cells in vivo. Results demonstrated that netrin-1 inhibition successfully decreased EMT in the transplanted A549 cells, validating the relevance of netrin-1 targeting for human cancer treatment and supporting the translational potential of this therapeutic approach.
PRIMARY OUTCOME
EMT reduction in transplanted A549 cells
EXPECTED OUTCOMES
Decreased EMT in A549 cells following NP137 treatment
SUCCESS CRITERIA
Significant reduction in EMT markers in transplanted human cancer cells
PROTOCOL
Transplantation of A549 cells into mice, TGFβ1-induced EMT, followed by NP137 treatment and EMT assessment
LINKED HYPOTHESES
Source: PMID 37532929 ↗
🧫 Experiment Extras
PATHWAY
Netrin-1 signaling pathway, TGFβ1-induced EMT pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.